Authors: Anne M. Spanjaart, Per Ljungman, Rafael de la Cámara, Gloria Tridello, Valentín Ortiz-Maldonado, Alvaro Urbano-Ispizua, Pere Barba, Mi Kwon, Dolores Caballero, Pierre Sesques, Emmanuel Bachy, Roberta Di Blasi, Catherine Thieblemont, Friso Calkoen, Pim G.N.J. Mutsaers, Johan Maertens, Livia Giannoni, Emma Nicholson, Matthew Collin, Carlos Pinho Vaz, Elisabetta Metafuni, Joaquin Martinez-Lopez, Fiona L Dignan, Josep-Maria Ribera, Arnon Nagler, František Folber, Robin Sanderson, Adrian Bloor, Fabio Ciceri, Nina Knelange, Francis Ayuk, Nicolaus Kröger, Marie José Kersten, Stephan Mielke

Venue: Blood

Type: Publication

Abstract: Abstract Background The ongoing Coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is having an enormous impact on society worldwide and is especially posing a threat to health in vulnerable patients, such as patients with immune deficiencies. It is expected that patients who received Chimeric Antigen Receptor T-cell (CAR T-cell) therapy for hematologic malignancies are at risk for poor outcomes after COVID-19 due to their severely immunocompromised state caused by prior cum... (read more)

DOI: 10.1038/s41375-021-01466-0 (Found 2 versions)